Turn Therapeutics Inc. (TTRX)
| Market Cap | 120.64M |
| Revenue (ttm) | n/a |
| Net Income | -3.84M |
| EPS | -0.14 |
| Shares Out | 29.79M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 29,429 |
| Open | 3.895 |
| Previous Close | 4.020 |
| Day's Range | 3.785 - 4.070 |
| 52-Week Range | 2.570 - 26.500 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 8.00 (+97.53%) |
| Earnings Date | May 11, 2026 |
About TTRX
Turn Therapeutics Inc., operates as a pharmaceuticals company that develops drugs to treat diseases of the skin, nails, and eye. The company's delivery technology penetrates the skin and nails and reduces antibiotic through acute and chronic wound care products, enabling healthcare institutions to care for a variety of skin conditions, ranging from acute to chronic wounds, skin conditions, and dermatoses. The company was formerly known as Global Health Solutions, Inc and change its name to Turn Therapeutics Inc. in September 2025. Turn Therapeu... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to one analyst, the rating for TTRX stock is "Strong Buy" and the 12-month stock price target is $8.0.
News
Turn Therapeutics reports Q1 EPS (3c) vs. (1c) last year
Cash and cash equivalents as of March 31, 2026 were $11.2 million as compared to $5.08 million as of December 31, 2025. “The first quarter of 2026 materially strengthened Turn…
Turn Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Updates
WESTLAKE VILLAGE, Calif.--(BUSINESS WIRE)--Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted inflammatory and immunological therapies for dermatologic c...
Turn Therapeutics reports FY25 EPS (12c) vs. (7c) last year
“Our first months as a public company have been highly productive, with strong progress across our clinical, financial, and strategic priorities,” said Bradley Burnam, Chief Executive Officer of Turn ...
Turn Therapeutics Reports Full Year 2025 Financial Results and Provides Corporate Updates
LOS ANGELES--(BUSINESS WIRE)--Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted inflammatory and immunology therapies for dermatologic conditions, today...
Turn Therapeutics secures up to $25M in financing
Turn Therapeutics (TTRX) entered into a growth capital loan facility with Avenue Venture Opportunities Fund II for up to $25M. The facility includes an initial $7M tranche funded at closing,…
Turn Therapeutics Secures Up to $25 Million in Financing From Avenue Capital Group
LOS ANGELES--(BUSINESS WIRE)--Turn Therapeutics, Inc. (Nasdaq: TTRX), a clinical-stage dermatology company developing novel therapies for inflammatory skin diseases, today announced it has entered int...
Turn Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference
A novel polymer-based ointment targeting IL-36/IL-31 is in phase II trials for moderate to severe eczema, with interim and top-line data expected in Q2 2026. The company also advances a phase III-ready onychomycosis drug and explores additional dermatology indications, supported by strong safety data and patent protection.
Turn Therapeutics Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference
The company is advancing a novel topical therapy for moderate to severe eczema, with a large phase II trial underway and interim results expected in Q2 2026. Its lead asset, GX-03, shows strong safety and efficacy, with plans for phase III trials in both eczema and onychomycosis.
Turn Therapeutics Appoints Dr. Robert Redfield as Senior Advisor of Health Policy and Regulatory Affairs
LOS ANGELES--(BUSINESS WIRE)--Turn Therapeutics, Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted inflammatory and immunology therapies for dermatologic conditions, toda...
Turn Therapeutics to Present at Upcoming TD Cowen and Oppenheimer Healthcare Conferences
LOS ANGELES--(BUSINESS WIRE)--Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted inflammatory and immunology therapies for dermatology, today announced t...
Turn Therapeutics Announces Corporate and Pipeline Updates and 2026 Outlook Ahead of the 44th Annual J.P. Morgan Healthcare Conference
LOS ANGELES--(BUSINESS WIRE)--Turn Therapeutics, Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted inflammatory and immunological therapies for dermatologic and infectiou...
Turn Therapeutics Appoints Martin Dewhurst to its Board of Directors
LOS ANGELES, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted inflammatory and immunology therapies for dermatology, ...
Turn Therapeutics initiated with a Buy at D. Boral Capital
D. Boral Capital initiated coverage of Turn Therapeutics (TTRX) with a Buy rating and $8 price target Turn is developing a dermatology-focused therapeutic platform to address inflammatory and immune-m...
Turn Therapeutics reports Q3 EPS (7c) vs (3c) last year
“Our first weeks as a public company have been extremely productive, and our continued execution brings us closer to achieving our immediate strategic goal of developing a portfolio of potential…
Turn Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Updates
Successfully began trading on NASDAQ under ticker TTRX on October 8, 2025 Strengthened its Board of Directors with the appointments of Arthur Golden and Dr. Kent Kester Entered into a global supply, d...
Turn Therapeutics CEO, Bradley Burnam, Speaks with Former Director of the Centers for Disease Control and Prevention Dr. Robert Redfield, M.D.
Conversation Centered Around Healthcare Communications and Pandemic Preparedness Conversation Centered Around Healthcare Communications and Pandemic Preparedness
Turn Therapeutics' GX-03 Technology Named as One of “Five Novel Mechanisms Reshaping Atopic Dermatitis Treatment” by Patient Care Online Magazine
LOS ANGELES, Nov. 11, 2025 (GLOBE NEWSWIRE) -- Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing dermatologic, advanced wound, and infectious disease therapies, ...
Turn Therapeutics Appoints Veteran Capital Markets Executive Andrew Scott as Vice President of Corporate Communications
LOS ANGELES, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing dermatologic, advanced wound, and infectious disease therapies, ...
Turn Therapeutics enters global supply, license agreement with Medline
Turn Therapeutics (TTRX) announced it has entered into a global supply, development, and license agreement with Medline, the largest provider of medical-surgical products and supply chain solutions se...
Turn Therapeutics Enters Global Supply, Development, and License Agreement with Leading Medical-Surgical Product Manufacturer and Distributor Medline
WESTLAKE VILLAGE, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Turn Therapeutics (Nasdaq: TTRX) (“Turn” or the “Company”), a clinical-stage biotechnology company developing next-generation dermatology, w...
Turn Therapeutics provides shareholder update on clinical program progress
Turn Therapeutics (TTRX) provides a shareholder update outlining continued progress in the advancement of its clinical programs while highlighting the flexibility of its financing strategy following i...
Turn Therapeutics Provides Shareholder Update Highlighting Continued Execution Across Clinical and Strategic Milestones
Company to host shareholder webinar today, October 22, 2025, at 2:00 PM ET to review execution milestones, pipeline progress, and capital strategy Company to host shareholder webinar today, October 22...
Turn Therapeutics launches webinar series for shareholder engagement
Turn Therapeutics (TTRX) announced the launch of a broad communications initiative, featuring a recurring webinar series for shareholders and a forthcoming Founder Blog authored by patient-turned-foun...
Turn Therapeutics Launches Webinar Series for Ongoing Shareholder Engagement, First Session October 22, 2025
LOS ANGELES, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Turn Therapeutics (Nasdaq: TTRX) today announced the launch of a broad communications initiative, featuring a recurring webinar series for shareholders a...
Turn Therapeutics appoints Kester to board of directors
Turn Therapeutics (TTRX) announces the appointment of Kent Kester, MD, FACP, FIDSA, FASTMH to its Board of Directors.